Theresa Carnegie's comments were featured in a PharmaVoice newsletter article analyzing the Biden administration's announcement of the first 10 drugs up for Medicare price negotiations. 

Theresa said, "Those quickly approaching deadlines could blunt the impact of price negotiations for the companies. For those individual manufacturers, it's probably neutral news, because from a financial impact perspective, those manufacturers were already projecting a loss of exclusivity and competition in the market."

Source

PharmaVoice Newsletter